VÄRSKENDUS Hematoloogia / onkoloogia 2024
ESMO kongress 2023
Datopotamab deruxtecan achieved the PFS endpoint for previously treated NSCLC. 177Lu PSMA-617 increases rPFS for metastatic castration resistant prostate cancer that is taxane-naive. Amivantamab combinations therapies are emerging as new options for EGFR mutated advanced NSCLC. Antibody-drug combinations improve outcomes for patients who have metastatic or inoperable breast cancer. Digital health technologies are revolutionising cancer care.
Kasutate oma veebibrauseri vanemat versiooni, mistõttu ei pruugita mõnda funktsiooni korralikult kuvada.
MINIMAALNÕUDED: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15–2.23.
Meeting Resources19 Oct 2023OncologyPRO now offers meeting resources: +3.000 slides and webcasts; abstracts and ePosters.Access to resources.
OncologyPRO pakub nüüd koosolekuressursse: +3.000 XNUMX slaidi ja veebiülekannet; kokkuvõtted ja ePosterid.
Daily ReporterDatopotamab deruxtecan reached the PFS endpoint for previously treated NSCLC23 Oct 2023TROP2-directed ADC increased PFS and reduced toxicity in comparison with chemotherapy, but the results of TROPION Lung01 are not practice changing.
TROP2-directed ADC increased PFS and reduced toxicity in comparison with chemotherapy, but the results of TROPION Lung01 are not practice changing.
Daily Reporter177Lu PSMA-617 parandab rPFS-i metastaatilise kastreerimisresistentse eesnäärmevähiga patsientidel, kes ei ole taksaani kasutanud.
Registreeru piletite või kabiinide saamiseks
Toimumiskoha kaart ja hotellid ümber
München – Holiday Inn München – kesklinn, Baieri, Saksamaa München – Holiday Inn München – kesklinn, Baieri, Saksamaa
Soovin uudiskirja